# A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

> **NCT07716098** · PHASE3 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 348 (estimated)

## Conditions studied

- Depressive Disorder, Treatment-Resistant

## Interventions

- **DRUG:** Esketamine 56 mg
- **DRUG:** Esketamine 84 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07716098
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-23
- **Primary completion:** 2028-12-27
- **Final completion:** 2029-09-12
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716098, "A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07716098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*